What the FDA labels say about taking them together
Cabozantinib and clarithromycin
Cabozantinib's FDA label (Cometriq) of October 18, 2025 names clarithromycin in its drug interactions section; the clarithromycin label PlainMeds reads does not name cabozantinib. The cabozantinib label: “Avoid taking a strong CYP3A4 inhibitor while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided.”
Check it at the source: the cabozantinib FDA label on DailyMed (effective October 19, 2025, Exelixis, Inc.); the clarithromycin FDA label on DailyMed (effective April 9, 2026, Solaris Pharma Corporation).
What does the cabozantinib label say about clarithromycin?
Cometriq label (Exelixis, Inc., October 18, 2025), drug interactionsAvoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )].
Source: FDA drug label (Cometriq, NDA203756), Exelixis, Inc., effective October 18, 2025 (SPL set 1a0c3bea-c87b-4d25-bb44-5f0174da6b34), via openFDA
Source: FDA drug label (CABOMETYX), Exelixis, Inc., effective October 19, 2025 (SPL set 3850cce2-6137-42e5-a792-d318c4a4b3b5), via openFDA; the full label on DailyMed
What does the clarithromycin label say about cabozantinib?
Clarithromycin's label (effective April 9, 2026) does not name cabozantinib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Clarithromycin), Solaris Pharma Corporation, effective April 9, 2026 (SPL set 4d42821d-ce7a-7d64-e063-6294a90a0875), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cabozantinib | Clarithromycin | |
|---|---|---|
| Labeled for | n/a | Bacterial infections, Acid reflux and ulcers |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $0.466 per tablet 500 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once